Cancer Survivor & Award-Winning Journalist, Jamie Reno, Announces Genelux Corporation's Advancement in Cancer Research
San Diego, CA (PRWEB) July 19, 2013 -- Jamie Reno, an award-winning journalist, cancer survivor and patient advocate, discussed in depth the discoveries by a small biotech firm in San Diego that has been flying under the radar for the past decade. What’s the big discovery? They may have found the cure for cancer.
While Genelux is currently conducting Phase I/II human trials for this virus at Moores, Sloan Kettering, Royal Marsden Hospital in London, and the Tubingen University Hospital in Germany, most people have not heard of this treatment, or this company. The virus-based treatment developed by Genelux, a company founded in 2001 that has offices in California and Europe, could completely change the perspective and approach on cancer care. Genelux, which has received very little publicity, has developed a virus-based treatment called GL-ONC1 that kills cancer cells throughout the body safely and effectively.
While there are plenty of so-called wonderdrugs that kill cancer in mice but do not work in people, the virus-based treatment from Genelux has been proven effective in people. Human trials for GL-ONC1 are already underway at such prestigious cancer institutions as Memorial Sloan-Kettering in New York and the UC San Diego Moores Cancer Center. More than 60 people, mostly patients who have exhausted every other treatment option, have enrolled in these trials for a variety of cancers. And the responses have been amazing.
Reno is not big on hype and hyperbole when it comes to cancer treatments, but the inspirational story of Genelux can serve as a beacon of hope for those who suffer from cancer, and often times, the toxic treatment that follows. Reno believes their work could result in an entirely new paradigm in the field of oncology and delivery of medicine in general.
The virus, which was used in the first smallpox vaccine nearly two centuries ago, is delivered intravenously, and then navigates through the body’s immune response to reach its target. It intelligently locates and kills all cancer cells throughout the body (solid tumors, liquid tumors, cancer stem cells, and metastasis). The treatment is very safe and there are no side effects other than very mild fever for and some chills for a few hours at most.
Using a virus to treat cancer is not a new study; it has been around for several decades. Besides vaccine, other oncolytic viruses used in clinical trials are adenovirus, reovirus, measles, herpes simplex and Newcastle disease viruses. But Genelux has taken it to new heights with this treatment, which could even be a cure.
About: Jamie Reno, an award-winning correspondent for Newsweek for 20 years, has also written for The Daily Beast, The New York Times, Sports Illustrated, Rolling Stone, People, Men’s Journal, ESPN, Los Angeles Times, TV Guide, MSNBC, Newsmax, Entertainment Weekly, and USA Today. Reno has won more than 95 writing awards including the National Magazine Award for General Excellence, the highest award in magazine journalism. Reno is also a three-time, 17-year survivor of stage IV non-Hodgkin's lymphoma. He has written two acclaimed books on cancer survivorship and is always on the lookout for new cancer treatments. He lives in San Diego with his wife, Gabriela, and their daughter, Mandy.
If you're a cancer patient or just want more information on Genelux or other companies that offer new, innovative cancer treatments, contact Jamie Reno directly.
Jamie Reno, http://therenodispatch.blogspot.com/2013/07/exclusive-does-san-diego-biotech-firm.html, 858-397-4950, [email protected]
Share this article